FDA approves 55 new drugs in 2023, one of the highest numbers in a decade

Infectious diseases, neurological diseases, type 2 diabetes in children, oncology and cardiac disorders are just some of the areas that benefited from the innovation drive last year. More than half of these innovations have orphan drug designation, i.e. they are intended for patients with rare diseases 36% have been classified as “first in class” because […]

The Distefar team is environmentally conscious and switches from buying single-use plastic bottles to glass bottles.

The pharmaceutical industry, a strategic sector for Spain and Europe

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. larazon.es Developing and producing new medicines for society is both a privilege and a great responsibility. As an innovative pharmaceutical industry, it is an honour to contribute to improving people’s health, but also to economic growth and social progress. […]

Paediatricians join project to boost clinical research in primary care

The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. Farmaindustria.es The drive for clinical research in Primary Care (PC) continues to advance in Spain. A new meeting of the mixed working group was held on Monday, comprising representatives of the Spanish Society of Primary Care Doctors […]

R&D investment in the pharmaceutical industry reaches 1.4 billion euros in Spain and grows by 10% in just one year

Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and pre-clinical research, the most complex and highest risk area. “Patients benefit most from this investment, because a large part of it is dedicated to launching clinical trials, a unique […]

“The European Health Data Space is an opportunity to gain greater efficiency in cancer drug research”.

Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. Farmaindustria.es “The proposed Regulation for the creation of the European Health Data Space presents a great opportunity in the field of efficiency for research and innovation not only for health systems, but also for […]

“Clinical trials are a hope for patients with rare diseases and already account for 25% of all research done in Spain”.

Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of Deputies. “The pharmaceutical industry will continue to work with patients to give them and their associations a greater voice,” he adds. Farmaindustria.es Finding new drugs for rare diseases is […]

Boosting clinical research in Primary Care, an opportunity for patients, professionals and the health system

Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in health centres. Spain’s leadership in clinical research at the hospital level is not reflected at the health centre level, where only 7.5% of studies are carried out. “Clinical research […]

“The European Health Data Space is a unique opportunity that will improve research and innovation for the whole of society.

The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For the pharmaceutical industry, the secondary use of data can complement the information from clinical trials and therefore improve the effectiveness of medicines,” says Pedro Luis Sánchez. farmaindustria.es The use […]

Farmaindustria’s protection of personal data in research is already a benchmark in Europe and is a further incentive to attract clinical trials to Spain.

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply with their obligations in the protection of data for scientific research purposes. That of the pharmaceutical industry was the first sectoral code approved by the Spanish Data Protection Agency […]